Hajir Dadgostar, MD
Ophthalmology · Encino, CANPI 1144427568
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.2%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Genentech, Inc. at 33.9% of the total. Reporting peaked in 2019 at $7,501 and has fallen 62.3% since, to $2,824 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $95.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$7K
- Apellis Pharmaceuticals, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- AbbVie$2K
- Alimera Sciences, Inc.$2K
- Eyepoint US, Inc.$2K
- plus $4K from 20 others
Across 631 payments — averaging $2424.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$568K
- Hexal AG$232K
- Ocular Therapeutix, Inc.$196K
- Kyowa Kirin, Inc.$167K
- Eyepoint US, Inc.$164K
- Genentech, Inc.$148K
- plus $54K from 3 others
What the payments were for
- Consulting fees$5,68027%
- Speaking & faculty fees$3,00014%
- Grants$1,2006%
- Travel & lodging$2,15410%
- Food & beverage$8,86142%
- Education$420%
- Gifts$190%
- Entertainment$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 10 | $7,118 |
| Apellis Pharmaceuticals, Inc. | 16 | $2,640 |
| Regeneron Healthcare Solutions, Inc. | 37 | $2,417 |
| AbbVie(2 entities) | 51 | $1,691 |
| Alimera Sciences, Inc. | 19 | $1,549 |
| Eyepoint US, Inc. | 11 | $1,507 |
| Genentech USA, Inc. | 33 | $1,152 |
| Kyowa Kirin, Inc. | 6 | $732 |
| Ocular Therapeutix, Inc. | 2 | $235 |
| Astellas Pharma US Inc | 2 | $226 |
| Coherus Oncology, Inc. | 5 | $219 |
| Novartis | 2 | $217 |
| Glaukos Corporation | 2 | $212 |
| Bausch & Lomb Americas Inc. | 4 | $194 |
| Alcon | 1 | $164 |
| Dutch Ophthalmic, USA | 1 | $148 |
| Sandoz | 5 | $117 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $107 |
| Regeneron | 3 | $100 |
| Biogen | 3 | $68 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Optos, Inc. | 1 | $42 |
| Amgen | 1 | $26 |
| Harrow Eye, LLC | 1 | $26 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucentis$5,361
- Syfovre$2,232
- SUSVIMO$1,680
- EYLEA$1,439
- EYP-1901$1,278
- Iluvien$1,106
- VABYSMO$407
- enVista MX60 IOL$256
- Izervay$226
- DEXTENZA$209
- Rocklatan$164
- Hydrus Microstent$164
- EVA, combined machine$148
- TISSUEBLUE$148
- iStent inject Trabecular Micro-Bypass Stent System$135
- Cimerli$132
- enVista Aspire IOL$128
- OZURDEX$125
- Non-Covered Product$111
- Tecnis Symfony IOL$107
How this compares
$20,998 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 29 | $11,568 |
| Bromfenac Sodium | 36 | $6,206 |
| Prednisolone Acetate | 138 | $5,472 |
| LumiganBimatoprost | 12 | $4,120 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,144 |
| MoxifloxacinMoxifloxacin Hcl | 58 | $1,123 |
| Atropine Sulfate | 35 | $1,057 |
| Brimonidine Tartrate | 79 | $970 |
| Ketorolac Tromethamine | 43 | $725 |
| Timolol Maleate | 41 | $381 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $256 |
| Latanoprost | 14 | $121 |
| Ofloxacin | 11 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $1,691 | $4,12012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Encino
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.